The growing introduction and spread on the market of biosimilar drugs can contribute to the economic sustainability of the healthcare system if the regulatory system at national and regional level provides guarantees and homogeneity to all involved. This must not lose sight of the potential that biotechnological innovation has in terms of economic development and improved treatments for patients. The event, promoted by Quotidiano Sanità, encouraged an in-depth debate on these topics, through the involvement of the most important political and regulatory institutions and of representatives of the most important scientific societies and patient associations. More than 100 people attended the event organized at the Ministry of Health in Rome.